All News

“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.

The fast track designation for 64Cu-SAR-bisPSMA is supported by findings from Clarity’s ongoing clinical program for the imaging agent.

“In the highly selected patient with localized MIBC, an organ-preserving approach to treatment may produce similar oncologic outcomes to radical surgery with a potential for improved QoL, although there is currently insufficient evidence to recommend bladder preservation therapy as a standard of care," the authors write.

Any stone fragmentation was achieved in 88% of patients.

A full market release of the HYDROS System is expected within the current quarter.

"Early-career physicians should ask themselves whether they really need to purchase a home right away or whether they would be better served renting for a few years," writes Jeff Witz, CFP.

"Overall, we found that patients with recurrent RCC following adjuvant IO continued to have responses to different types of first-line systemic therapy," says Talal El Zarif, MD.

The approval for enfortumab vedotin is supported by findings from the global phase 3 EV-301 trial and the phase 2 EV-203 bridging trial in Chinese patients.

"The great news is that we have now completed recruitment. We actually recruited more than 1700 patients," says Kari A.O. Tikkinen, MD, PhD.

The phase 1 trial is assessing the safety and tolerability of MOMA-313 as both a monotherapy and in combination with olaparib in patients with HR-deficient advanced or metastatic solid tumors.

"But here at IU, we have an experimental protocol that's open that's called testicular tissue cryopreservation, and it's a collaboration with UPMC," says Amanda J. Saraf, DO.

William Tabayoyong, MD, PhD, highlights the University of Rochester’s upcoming Bladder Cancer Symposium, which will take place on September 14, 2024.

"The updated guideline includes numerous new, important recommendations that will enhance the ability of urologists to provide optimal, state-of-the-art care for infertile males,” says Robert E. Brannigan, MD.

"Combining PRIMARY and PI-RADS scores could be a game-changer in how prostate cancer is diagnosed," says Louise Emmett, MBChB, FRACP, MD.

Per Kaplan-Meier estimates, 95.6% of patients who underwent SURE were free of health care consumption events by 12 months, compared with 83.5% of patients who underwent URS.

“The challenge now is to understand how these key aspects of mitochondrial metabolism become activated, why they stimulate metastasis, and whether we can safely block them,” says Ralph J. DeBerardinis, MD, PhD.

The NDA for UGN-102 is primarily supported by findings from the phase 3 ENVISION trial.

"I think the patients that benefit the most are patients that have certain types of stones that potentially are much harder to treat with some of the more minimally invasive types of procedures," says John Michael DiBianco, MD.

Data from a real-world evidence study of the Leva System were recently published in JMIR Formative Research, supporting the safety and effectiveness of the program in the treatment of patients with urinary incontinence.

Patient recruitment for the phase 2 trial is expected to begin by the end of 2024.

With this designation, the development process for 9MW2821 can benefit from prioritized engagement with China’s Center for Drug Evaluation as well as expedited review and approval.

The phase 1/2 trial is assessing the safety, tolerability, radiation dosimetry, and preliminary anti-tumor activity of 225Ac-rhPSMA-10.1 in men with mCRPC.

"We propose a new classification system, which we believe will provide a more consistent and standardized approach to classification and treatment of PD," says Landon Trost, MD.

"By helping them see what could be going on with their health and knowing when to reach out for help, we think that's a fantastic way to begin to change the paradigm when it comes to men and prostate cancer in the US," says Motolani Adedipe, PhD, DPh, MSc.

The median PFS with PSMA PET/CT-guided MDT was 33.2 months, vs 13.8 months with choline PET/CT-guided MDT.

Data from the study showed that 45% of biopsies with benign results or low-grade cancers could be reduced overall by using Stockholm3 compared with PSA.

"If we don't take the time to speak to trainees, an already vulnerable population, we're missing an opportunity to help them early," says Andrew M. Harris, MD.

“Our data suggest that an MRI can show suspicious lesions based on size and markers of tumor aggression, which may help doctors differentiate a treatment path for these patients," says Kiran R. Nandalur, MD.

"The scale of that linkage and the manner with which we were able to do it is really exciting and opens the door for a lot of future discovery," says Michael S. Leapman, MD, MHS.

The prognostic test has now been validated in patients who have undergone active surveillance, radiation therapy, or had a radical prostatectomy.